We Work for Health | Washington

11/05/2025

"Some of our largest and wealthiest hospital systems are reaping millions of dollars from marking up discounted drugs meant for our underserved ."

isn't working as intended for patients: https://www.chicagotribune.com/2025/10/24/opinion-chicago-hospital-drug-price-aid-university-of-chicago-medicine-rush-medical-center/

11/03/2025

"When PDABs prioritize financial considerations over the reality of what a patient needs in that moment, they create artificial barriers that disrupt care. Healthcare should respond to patient needs—not the other way around."

https://www.healthaffairs.org/sponsored-content/national-minority-quality-forum/state-prescription-drug-affordability-boards-when-cost-takes-precedence-over-patient-health

10/31/2025

: Incubate Policy Lab's report examines how certain policies are slowing innovation in the U.S. while China is taking steps to accelerate it.

Read the report: https://www.incubatecoalition.org/post/one-pager-united-states-policies-slow-biotech-while-china-accelerates

10/30/2025

"The direct-to-patient model has several benefits. It protects patients from surprise charges at the pharmacy counter. It limits the ability of middlemen to raise prices behind the scenes. And it offers a way to lower patient costs without jeopardizing innovation."

https://dcjournal.com/this-overlooked-trump-proposal-could-be-the-key-to-lower-drug-prices/

10/29/2025

"Drug manufacturers have an expectation that their investments will be recouped in the United States; otherwise, many much-needed drugs would never be developed at all."

Protect American leadership and innovation: https://www.washingtontimes.com/news/2025/oct/21/no-global-freeloading-medical-innovation/

10/28/2025

TOMORROW: Senate members are holding a hearing on U.S. competitiveness and accelerating cures for patients.

China is expanding biopharma R&D to challenge U.S. leadership. We must keep America at the forefront of innovation.

WASHINGTON – On Wednesday, October 29, the Senate Health, Education, Labor, and Pensions (HELP) Committee will hold a hearing on how we can better...

10/27/2025

Policymakers must ensure America stays ahead: Senate leaders will hold a hearing Wednesday on the battle for biopharma leadership, clinical trials and IPO expansion in China, and investments in R&D and infrastructure in the U.S.:

WASHINGTON – On Wednesday, October 29, the Senate Health, Education, Labor, and Pensions (HELP) Committee will hold a hearing on how we can better...

10/24/2025

Why leave middlemen off the chopping block?

Insurers are raking in record profits while taxpayers
pay. Insurance reform has the potential to save hundreds of billions and lower costs for families.


https://www.foxbusiness.com/economy/medicare-advantage-plans-may-cover-things-like-pet-food-golf-fees-ski-passes

10/22/2025

Washington looked the other way while corporate middlemen hijacked Medicare.

Taxpayers are footing the bill for hundreds of billions in waste and fraud. It’s time to fix it.

https://www.legalnewsline.com/legislation-and-government/no-upcode-act-could-be-part-of-shutdown-solution-and-more/article_92334a28-1c01-40c0-8fd2-b50681f8c2b1.html

10/20/2025

"The North Carolina State treasurer found 340B hospitals overcharged state employees for cancer drugs, with an average markup of over five times the discounted acquisition price."

Established to help our most vulnerable patients access essential medications, the well-intentioned federal 340B program has been hijacked by large hospital and pharmacy systems, thereby raising health care costs for all Virginians by inflating the cost of the discounted drugs.

10/17/2025

"President Trump is trying to expand that price control regime by instituting a Most Favored Nation policy, which would anchor U.S. drug prices to the artificially low prices that prevail in Italy and other European countries."

won't work in the U.S.: https://www.realclearhealth.com/articles/2025/10/09/americans_should_copy_italians_recipes_not_our_healthcare_system_1139780.html

10/15/2025

"In any normal market—whether it’s a retail outlet or a grocery store—prices are clearly displayed for consumers to see and make their purchasing decisions accordingly. But when it comes to pharmaceuticals, patients often have no idea what their prescription costs overall, what their share of the bill will be at the pharmacy counter, and what alternatives exist."

Patients sense they’re being taken advantage of — and they’re often correct. Direct-to-consumer sales enable Americans to cut out the middlemen.